What concentrations and routes the GHK-Cu studies actually used

How to read GHK-Cu research doses by model

GHK-Cu research doses by model span an enormous range — from picomolar in a culture dish to milligrams per kilogram in a rodent — because "dose" means something different in each setting. None of the figures below is a human protocol. Topical Copper Tripeptide-1 is a legal cosmetic ingredient, but injectable, oral and other systemic use of GHK-Cu is not approved by any regulatory body, and the systemic doses listed here are the amounts administered to animals in published experiments, recorded for completeness, not as instructions ^[6].

The foundational concentration is the picomolar-to-nanomolar fibroblast range. Collagen synthesis began between 10⁻¹² and 10⁻¹¹ M and peaked near 10⁻⁹ M in human cell culture ^[1]. That is the concentration at which the peptide's signaling effect appears — far below anything used systemically — and it anchors why the molecule is described as potent rather than abundant.

Topical and cosmetic concentrations

In cosmetic and dermatologic use, GHK-Cu appears in creams, serums and gels at roughly 0.05% to 2% (w/w) ^[13]. The 2024 hair microemulsion used 2% GHK-Cu delivered to mouse scalp, at the upper end of that band ^[14], and the human hair-loss trial used its 5-ALA + GHK complex at 50–100 mg/mL topically ^[4]. These are the concentrations recorded in the studies; they describe what was applied in an experiment, not a recommended regimen.

The more important topical variable is not percentage but delivery. Because native GHK penetrates poorly (clogP −2.24), two products at the same labeled concentration can deliver very different amounts of intact complex to the dermis ^[13]. A human penetration study measured 97 µg/cm² of copper retained as a dermal depot over 48 hours when delivered as the tripeptide, confirming that meaningful transfer is achievable but formulation-dependent ^[5]. The copper peptide skin research page covers the enhancement strategies in detail.

Routes studied in animal research

Beyond topical use, the published rodent literature has explored several systemic routes — again, in animals, and again recorded here only to describe the research. Mouse pulmonary studies used intraperitoneal GHK-Cu at 0.2, 2 and 20 µg/g/day on alternate days for emphysema and at higher concentrations for fibrosis models; silicosis models used 2 and 20 mg/kg ^[6]. Mouse DSS-colitis work used 20 mg/kg by oral gavage daily, and aging and cognition studies used intranasal GHK at 15 mg/kg ^[6]. Rat behavioral studies used much smaller intraperitoneal amounts, on the order of 0.5 µg/kg to 0.5 mg/kg ^[6].

The spread across intraperitoneal, intranasal, oral-gavage, intravenous and intradermal routes reflects researchers probing different tissues, not a consensus delivery method ^[6]. For humans, the only routes with any controlled clinical data are topical: small dermatology trials and the one 45-patient hair-loss study ^[3][4]. Injectable and systemic human protocols circulating in community settings have no peer-reviewed pharmacokinetic basis.

Half-life and stability: what the literature supports

No rigorous human pharmacokinetic half-life has been published for GHK-Cu. The free tripeptide (340.38 Da) is cleared rapidly by plasma peptidases — a rat study documented rapid metabolism of GHK to the dipeptide HK after intravenous dosing — and secondary literature cites a short systemic elimination half-life on the order of 1–2 hours, with the copper-chelated complex more stable than free GHK ^[6]. Any specific human half-life number should be treated as an estimate, not a measurement.

Topical behavior is the better-characterized half of the story. Rather than a circulating half-life, topical GHK-Cu forms a dermal copper depot — about 97 µg/cm² retained over 48 hours — which gives prolonged local availability from the skin reservoir ^[5]. On the shelf, stability comes from the complex's high copper stability constant (log K about 16.4): it is most stable near pH 5–6.5 at a 1:1 copper-to-peptide ratio, and its blue-violet color indicates an intact Cu(II) complex, while brown or green shifts indicate oxidation or precipitation ^[6].

Why none of these numbers is a human protocol

It is worth stating plainly why the figures on this page stop where they do. GHK-Cu has no FDA- or EMA-approved therapeutic indication by any route, so there is no labeled dose to quote and no titration schedule to describe ^[6]. Topical Copper Tripeptide-1 is a legal cosmetic ingredient, which is why the 0.05–2% formulation range exists in a regulated commercial context — but injectable, oral and other systemic use is unapproved and research-only ^[6].

The systemic doses recorded above all come from animal experiments and are reported in their native units — micrograms per gram, milligrams per kilogram — because that is how the studies expressed them, not because they convert to a human amount. They do not. The rodent studies that used the heaviest copper loads stayed below the roughly 35 mg/kg ion-toxicity threshold, and a theoretical copper-accumulation or copper-zinc-balance concern is flagged for any prolonged systemic use ^[6]. The dosing protocols that circulate in community settings for injectable GHK-Cu have no peer-reviewed pharmacokinetic basis, which is the single most important caveat for anyone reading numbers like these.

For research framing, one further note: GHK-Cu is not currently listed on the WADA Prohibited List as of the 2024–2025 lists, distinct from some other research peptides, though WADA's catch-all category can cover non-approved pharmacological substances, so any athletic-research context should verify the current list directly ^[6]. This page exists to document what the literature recorded, sorted into clean capsules — the GHK-Cu research findings and the GHK-Cu citations and references carry the studies behind every number.